Merrimack Pharmaceuticals
MACK
$14.98
Share price
1.63%
Change (1 day)
18.98%
Change (1 year)
Categories
Merrimack Pharmaceuticals (MACK) - P/B ratio
P/B ratio as of May 2024 : 11.6
According to Merrimack Pharmaceuticals's latest financial reports the company has a price-to-book ratio of 11.6.
The price-to-book ratio is a way to measure how much the stock market thinks a company is worth compared to how much the company says its assets are worth on paper.
Merrimack Pharmaceuticals - P/B ratio (from 2012 to 2023)
P/B ratio by year
| Year | P/B ratio | Change |
|---|---|---|
| 2023-12-31 | 10.2 | 28.3% |
| 2022-12-31 | 7.98 | 116.04% |
| 2021-12-31 | 3.70 | -35.83% |
| 2020-12-31 | 5.76 | 136.58% |
| 2019-12-31 | 2.43 | 178.03% |
| 2018-12-31 | 0.8756 | -38.31% |
| 2017-12-31 | 1.42 | -167.81% |
| 2016-12-31 | -2.09 | -58% |
| 2015-12-31 | -4.98 | -57.81% |
| 2014-12-31 | -11.8 | -6.79% |
| 2013-12-31 | -12.7 | -86.06% |
| 2012-12-31 | -90.9 | |
| 2011-12-31 | N/A | |
| 2010-12-31 | N/A |
P/B ratio for similar companies or competitors
| Company | P/B ratio | differencediff. | Country |
|---|---|---|---|
 Sanofi SNY | 1.52 | -86.92% | 🇫🇷 France |
 Geron GERN | 9.69 | -16.55% | 🇺🇸 USA |
 Clovis Oncology CLVS | -0.0282 | -100.24% | 🇺🇸 USA |
 AVEO Oncology
AVEO | 18.1 | 55.68% | 🇺🇸 USA |
 Eterna Therapeutics ERNA | 4.31 | -62.86% | 🇺🇸 USA |